Omega-3 and the Ageing Brain: Why the Ratio Matters More Than the Dose

Omega-3 is one of the most written-about supplements in nutrition. It is also one of the most poorly understood in practice — not because the evidence is weak, but because most of the content written about it stops at “eat more oily fish” without addressing the variables that determine whether omega-3 actually does what the research shows it can do.

For women in perimenopause, three things matter specifically: the ratio of omega-3 to omega-6 in the diet (which most people have badly wrong), the direct evidence for omega-3’s effect on biological age clocks (which is now genuinely strong), and the question of bioavailability (which determines whether a supplement closes the gap or simply passes through). This post covers all three.

The ratio problem — why omega-6 undermines omega-3

Omega-3 and omega-6 fatty acids are not simply two different nutrients — they compete for the same enzymes, the same cell membrane incorporation sites, and the same metabolic pathways. The ratio between them in the diet directly influences the balance between pro-inflammatory and anti-inflammatory eicosanoids, which in turn influences systemic inflammation, neuroinflammation, and the chronic low-grade inflammatory state — inflammageing — that drives biological age acceleration.

The ancestral human diet is estimated to have had an omega-6 to omega-3 ratio of approximately 2:1 to 4:1. The typical modern Western diet delivers a ratio of approximately 15:1 — some estimates put it as high as 20:1. This imbalance is almost entirely driven by the widespread use of seed oils (sunflower, rapeseed, corn, soybean) in ultra-processed food manufacturing and cooking. These oils are rich in linoleic acid (an omega-6), which competes directly with EPA and DHA for the desaturase enzymes that convert dietary fatty acids into their biologically active forms.

The practical consequence: eating more omega-3 while maintaining a high omega-6 intake — through ultra-processed food, frequent takeaway meals, or cooking predominantly with seed oils — significantly blunts the anti-inflammatory effect of the omega-3. Correcting the ratio requires both increasing omega-3 and reducing omega-6 load. This is not discussed in most omega-3 content, but it is the single most important contextual factor in whether supplementation or dietary increases actually produce the outcomes the evidence predicts.

The biological age evidence — the DO-HEALTH trial

Until recently, most of the evidence for omega-3 and biological ageing was observational — higher dietary omega-3 associated with lower epigenetic age acceleration, but no large randomised controlled trial to confirm the direction of causality. That changed in February 2025 with the publication of the DO-HEALTH Bio-Age trial in Nature Aging.

The study — Bischoff-Ferrari et al., led by researchers at the University of Zurich with co-authorship from Steve Horvath (the researcher who developed the original Horvath epigenetic clock) — analysed DNA methylation data from 777 participants in the DO-HEALTH randomised controlled trial. Participants received 1g per day of omega-3, 2,000 IU per day of vitamin D, a home exercise programme, or combinations of these, for three years. The key findings:

• Omega-3 alone significantly slowed the PhenoAge, GrimAge2 and DunedinPACE epigenetic clocks over 3 years, with standardised effects ranging from 0.16 to 0.32 units — equivalent to approximately 2.9 to 3.8 months of slower biological ageing.
• All three interventions combined (omega-3 + vitamin D + exercise) showed additive benefits on PhenoAge — the combination effect was greater than any single intervention alone.
• The omega-3 effect was observed independently of vitamin D and exercise — confirming it as a genuine independent variable, not confounded by overall health behaviour.

This is the first large RCT to demonstrate that omega-3 supplementation measurably slows DNA methylation-based biological ageing in humans. It is worth being precise about what the effect size means: 3–4 months over 3 years is a modest effect, not a dramatic one. But it is an effect on the clocks themselves — the same clocks that predict mortality, disease risk, and functional decline — and it was achieved with a single gram per day from a standard supplement. Read the full DO-HEALTH Bio-Age paper here.

DHA and the perimenopause brain — the neuroinflammation pathway

The DO-HEALTH trial used a mixed EPA/DHA supplement. For perimenopause-specific cognitive symptoms, DHA is the more directly relevant fatty acid — and the mechanism connects directly to the neuroinflammation pathway covered in the brain fog post.

A 2026 review published in PMC — “Omega-3 fatty acids, brain health and the menopause” — synthesised the current evidence specifically for the menopause transition. The review found that EPA and DHA supplementation offers meaningful potential for menopause transition-associated vasomotor symptoms, brain fog, low mood, and anxiety, through several mechanisms:

• Neuronal membrane fluidity — DHA is the primary structural fatty acid in brain cell membranes, constituting approximately 97% of the omega-3 in the brain. Adequate DHA maintains the fluidity of neuronal membranes, which directly affects receptor sensitivity, synaptic plasticity, and signal transmission speed. As oestrogen declines in perimenopause and insulin resistance in brain tissue increases, DHA’s membrane-supporting role becomes more critical — it supports the structural environment that neurons need to function efficiently.
• Neuroinflammation reduction — EPA is converted to resolvins and protectins, specialised pro-resolving mediators (SPMs) that actively switch off the inflammatory cascade once triggered. In the context of the gut-dysbiosis-driven neuroinflammation covered in the brain fog post, EPA’s SPM production provides a complementary anti-inflammatory effect — addressing neuroinflammation from the top down (via SPMs) while gut health interventions address it from the bottom up (via butyrate and gut barrier integrity).
• BDNF support — DHA supplementation has been associated with increased brain-derived neurotrophic factor (BDNF) expression in several studies. BDNF is the primary growth factor for hippocampal neurons — the cells most responsible for memory consolidation and new learning. BDNF declines with age and with chronic stress (both of which converge in perimenopause), and DHA appears to partially buffer this decline.
• HPA axis modulation — EPA and DHA influence hypothalamic-pituitary-adrenal (HPA) axis reactivity. Several trials have found that omega-3 supplementation reduces cortisol response to acute stressors and blunts HPA hyperreactivity. In perimenopause, where cortisol dysregulation contributes directly to cognitive symptoms, sleep disruption, and biological age acceleration, this HPA-modulating effect is clinically relevant. Read the full review here.

The bioavailability problem — why most fish oil supplements underperform

This is the part of the omega-3 conversation that the supplement industry is least eager to discuss. Not all omega-3 is absorbed equally, and the form in which it is delivered determines how much EPA and DHA actually reaches the tissues that need it.

Most standard fish oil supplements — including the majority of high-street brands — deliver omega-3 in ethyl ester (EE) form. Ethyl esters are a concentrated, manufactured form produced by transesterification during the purification process. They are cheaper to produce and easier to standardise. They are also significantly less bioavailable than the natural triglyceride (TG) form in which omega-3 occurs in fish.

Multiple comparative absorption studies have quantified this difference. A review of the bioavailability literature found that triglyceride-form fish oil achieves approximately 124% relative bioavailability compared to ~73% for ethyl ester form — roughly a 70% improvement in absorption for the same stated dose. A separate study found EPA absorption from triglyceride form reached ~90% versus ~60% for ethyl ester. The practical implication: a 1,000mg ethyl ester capsule delivers meaningfully less EPA and DHA to the body than the same stated dose in triglyceride form.

The DO-HEALTH trial — which demonstrated the epigenetic clock effects — used a triglyceride-form supplement. This is not a coincidence. Triglyceride-form omega-3 is also better absorbed when taken with food, particularly a fat-containing meal, as the presence of dietary fat stimulates bile secretion and enhances lipid emulsification. Ethyl ester forms show even greater variability in absorption depending on whether they are taken with food or fasted.

Other factors that improve omega-3 bioavailability and efficacy: molecular distillation to remove heavy metals and PCBs (a quality marker for any supplement), sourcing from small pelagic fish (sardines, anchovies, mackerel) rather than large predatory fish (which bioaccumulate toxins), and phospholipid-form omega-3 from krill, which some research suggests may deliver superior brain uptake due to the phospholipid’s greater affinity for neuronal membranes.

Food sources and practical targets

The foundation of omega-3 intake should always be dietary — not because supplements are problematic, but because oily fish deliver DHA and EPA alongside a broader nutritional matrix (selenium, iodine, vitamin D, B12, high-quality protein) that amplifies the biological effect.

Practical dietary targets:

• Oily fish three times per week: Sardines, mackerel, wild salmon, herring, anchovies. A 100g serving of sardines delivers approximately 1.5–2g of EPA and DHA combined. Mackerel delivers approximately 2.5g per 100g serving — one of the richest practical sources.
• Walnuts daily: The only nut with a meaningful ALA (alpha-linolenic acid) content — the plant-form omega-3. The conversion of ALA to EPA and DHA in humans is limited (approximately 5–10%), but walnuts additionally provide polyphenols and ellagitannins with their own anti-inflammatory properties.
• Ground flaxseed: High in ALA, and as covered in the seed cycling post, the lignans in flaxseed support the estrobolome independently of the omega-3 content.
• Chia seeds, hemp seeds, edamame: Plant-based ALA sources. Useful for diversity but not equivalent to marine EPA/DHA in terms of neurological effect.

For women in perimenopause who are not reliably eating oily fish three times per week, a high-quality triglyceride-form supplement providing at least 1g of combined EPA/DHA per day is a reasonable and evidence-based addition. The DO-HEALTH trial used 1g per day — and that is the dose for which there is now RCT-level evidence for biological age effects. Higher doses may be appropriate for specific clinical contexts (cardiovascular risk, significant cognitive symptoms) but are outside the scope of this post.

Sources

• Bischoff-Ferrari HA et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 2025. https://www.nature.com/articles/s43587-024-00793-y
• PMC Review. Omega-3 fatty acids, brain health and the menopause. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12209554/
• Steady-state bioavailability of prescription omega-3 on a low-fat diet. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3794864/
• Short Hills Eye. Fish Oil Triglycerides vs Ethyl Ester: Which Absorbs Better? https://shorthillseye.com/blog/fish-oil-triglycerides-vs-ethyl-esters/

This article is for general information and does not constitute medical advice. Please consult your GP or a registered practitioner before making significant dietary or supplement changes.